ACU - Australian Cancer Technology

[Sandgroper]

Anyone know about this one?

Is there a doctorB in the house? :D

[stolwyk]

POST 1 of 2:

ACU--Australian Cancer Technology Ltd:

Website: http://www.austcancer.com.au/

BigChart:
http://bigcharts.marketwatch.com/javachart/javachart.asp?symb=AU%3A+ACU&time=&freq=

Shares: 102.9 mill. Unlisted options: 11.6 mill, 2004-2007.

Quarterly report: 31 March: Outflow: $0.9 mill. Cash: $3.618 mill.

April 30, 2001: Name change from "Exodus" to "ACU"

Jan. 14, 2004: AustCancer Growth To Include New USA & UK Projects:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=253480

Febr. 20, 2004: AustCancer to List on NASDAQ (ADR, Level 1):
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=255790

March 11, 2004: AusCancer Shareholder Newsletter:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=257252


PROJECTS

1. CANCER VACCINE: PENTRIX (TM)
Febr. 8, 2001: Exodus Minerals Limited ("Exodus"), renamed ACU later on, announces today (Thursday) that it has acquired the right to commercialise cancer vaccine technology developed from research into the human anti-p53 antibodies discovered by St Vincent's Hospital Sydney ("St Vincent's"), New South Wales.( 3 pages):
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=191379

April 11, 2001: Progress on p53 Cancer Vaccine:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=194590

Oct. 2, 2001: Clinical Trials for Pentrix Cancer Vaccine Commenced
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=202869

Oct 25, 2001: Publication of Pentrix Technology in International Journal
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=204303

Dec. 20, 2001: Breast Cancer Drug Discovery Program Ahead of Schedule.
Retroviral Display(TM) technology permits the discovery of 'drug-like' compounds which bind to cell receptors of the tryosine kinase family (C-erbB) that are overexpressed on the surface of cancer cells and are associated with growth or progression of many forms of cancer.

The gene responsible for production of C-erbB is overexpressed in 25% of breast cancers. The growth factor Heregulin is used as a "decoy" in the assay:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=207862

Jan. 23, 2002: Strengthens International Strategic Alliance ; second project (2 parts):
In the new joint venture, BioFocus and AustCancer will work together to identify potent and selective Chk1 kinase inhibitor compounds for development as potential cancer treatments.
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=209728

Jan. 30, 2002: Pentrix Anti-Cancer Vaccine Trial Successfully Completed:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=210059

Febr 22, 2002: Major cancer trial commenced (Phase 1b/2a)- Pentrix:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=211491

April 30, 2002: Penetrix Vaccine Clinical Trials Progressing Rapidly:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=215356

Nov 20, 2002: Strong Results from St Vincent`s Cancer Vaccine Human (Phase 1b/2a)Trials:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=227501

Dec 12, 2002: Commercialisation of the Pentrix Anti-Cancer Vaccine:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=229549

http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=230832

Febr 26, 2003: Successful Cmptln of Pentrix Clinical Trials At St Vincent`s. New Patent Application.
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=233420

May 8, 2003: Fellow biotechnology company, BresaGen (ASX:BGN), will collaborate with AustCancer by manufacturing a highly purified version of the p53 molecule, the ultimate target of AustCancer's Pentrix vaccine.
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=237314

July 2, 2003: Discussion of Phase II Trials for Anti-Cancer Vaccine:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=239789

http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=252514

April 13, 2004: Phase II Pentrix trial to commence:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=259169

http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=260494

Gerry
Readers, please do your own research and you decide if and when to buy,

[stolwyk]

POST 2 of 2:

2. BIOFOCUS PLC--HEREGULIN PROJECT
July 11, 2001: International strategic alliance & Joint Venture signed. A Strategic Alliance and unincorporated 50:50 Joint Venture with BioFocus plc (BioFocus), a leading UK based drug discovery and chemistry provider, has secured for Australian Cancer Technology Limited (Au stCancer) a pipeline of potential treatments for cancer.

BioFocus have developed an innovative and proprietary cell based ssay technology, "Retroviral Display(TM)" which permits the discovery of "drug-like" compounds which bind to cell receptors of the tryosine kinase family (C-erbB) that are overexpressed on the
surface of cancer cells and has been associated with growth or progression of many forms of cancer.

The gene responsible for production of C-erbB is over expressed in 25% of breast cancers. The growth factor HEREGULIN is used as a "decoy" in the assay.
There are no other known screens for C-erbB activity or binding:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=198637

May 13, 2002: Major advance in Breast Cancer Program:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=216126

Aug. 19, 2002: Partners agree to accelerate RVD Breast Cancer Programme:
Following exciting discoveries in the RVD (Retroviral Display) breast cancer therapeutic programme, Australian Cancer Technology (AustCancer) (ASX: ACU) and its UK partner BioFocus plc, have approved Stage 2 of the project and agreed to accelerate expenditure and increase the number of scientists working on the project:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=221532

Sept. 1, 2003: Important Cancer Drug Discovery from AustCancer JV.
The partners have decided to focus their development resources on the Chk1 Kinase project as it is believed it has the stronger potential to deliver commercial outcomes in the near term.
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=243300

3. ACQUISITION OF GALENICA PHARMA INC.
May 21, 2003: The Board of Australian Cancer Technology ("AustCancer") (ASX:ACU) announced today that it had signed an agreement to acquire, through its wholly-owned U.S. subsidiary Adjuvantys Inc., the business of Galenica Pharmaceuticals Inc., a private U.S biopharmaceutical company, for US$5.0 million in a largely scrip offer. Approximately US$12.0 million has been invested in the development.
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=330291


4. MS-MULTIPLE SCLEROSIS
July 18, 2000: Enters Biotechnology Field/Right to acq interest in MS Proj (2 parts):
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=181494

Oct. 23, 2000:Multiple Sclerosis Project Due Diligence Completed (2 parts):
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=186005

Oct 23. 2000: Murdoch Researcher Isolates MS Virus:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=186050

No further data available.


5. ADDITIONAL RESEARCH.
Nov. 13: Researchers Find Genetic Clue to Cancer Relapse:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=249636


6. CANCER CARE BUSINESS
Aug. 14: Acquisition of US Cancer Care Business
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=242251

Febr. 3, 2004: Top US Healthcare Grp Sign Deal to Distribute Nutraceuticals
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=254795

April 19, 2004: US Oncology Center to Offer ACU's revisys Supplements:
http://stocknessmonster.com/news-item?S=ACU&E=ASX&N=259536

Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.

Sandgroper I don't know about a Doctor but there is a Ramper

[stolwyk]

The man with the acid tongue.

Suggest you instead study the Announcements and comments from Management.


So, in case you won't understand, this is an ASX record only.

[tracker]

made my night Enigma
lol
stops as always
tracker